Tesla Q4 revenue up by 2% to $25.7B, misses estimates - Breaking The News
Download our appPlay StoreApp Store

Tesla Q4 revenue up by 2% to $25.7B, misses estimates

EPA-EFE/CAROLINE BREHMAN

Tesla Inc. revealed on Wednesday that its revenue in the fourth quarter of fiscal 2024 landed at $25.7 billion, representing an annual increase of 2% and missing estimates. At the same time, diluted earnings per share missed analysts' expectations and came at $0.73, growing 3% compared to the same quarter of 2024. Net income (GAAP) declined 71% year-on-year to reach $2.31 billion.

For fiscal 2024, the American multinational automobile giant's total revenue stood at $97.69 billion, rising 1% on a yearly basis, while net income (GAAP) slumped 53%, settling at $7.09 billion compared to the year prior.

"In 2024, we made significant investments in infrastructure that will spur the next wave of growth for the company, including vehicle manufacturing capabilities for new models, AI training compute and energy storage manufacturing capacity," the company stated. Tesla's stock increased 3.32% in the after-hours trading following the reports's release, selling for $389.10 apiece.

Related Stocks
Tesla
Related News
McDonald's revenue in Q1 at $5.9 billion, down 3%
McDonald's Corporation announced on Tuesday that its revenue in the first quarter of fiscal 2025 came in at $5.9 billion, down 3% on an annual level, and below market estimates.In the three months ending March 31, year over year, while net income decreased 3% to stand at $1.87 billion, diluted earnings per share slumped by 2%, amounting to $2.60. Operating income in the reported trimester saw a dip of 3%, coming in at $2.64 billion."McDonald's has a...
Biogen logs Q1 revenue of $2.4 billion, up 6%
Biogen Inc. revealed on Thursday in a press release that its total revenue in the first trimester of its fiscal 2025 amounted to $2.4 billion, up 6% compared to the same timeframe in 2024.Meanwhile, in the reported period, GAAP diluted earnings per share slumped year over year to reach $1.64. In addition, net income attributable to Biogen Inc. in the three months ending March 31 came in at $240.5 million."Biogen delivered strong first-quarter results, supporting...
Eli Lilly's Q1 revenue up 45% to $12.7 billion
Eli Lilly declared on Thursday that its revenue for the first quarter of fiscal 2025 increased 45% to $12.73 billion, driven by volume growth from Mounjaro and Zepbound. The company reported a first-quarter net income of $2.76 billion, up 23% year-over-year, driven by booming sales of its weight-loss and diabetes drugs. Earnings per share reached $3.06 despite absorbing $1.57 billion in acquired in-process R&D charges. CEO David Ricks highlighted the success of...
Moderna posts $1 billion net loss in Q1 2025
Moderna reported a $1 billion net loss for the first quarter of 2025 on Thursday, as revenues dropped to $108 million from $167 million a year earlier. According to the report, the loss translated to $2.52 per diluted share, driven by sharply reduced COVID-19 vaccine sales and continued seasonal softness in demand. The company's lead product, Spikevax®, generated $84 million in global sales during the quarter. "Looking ahead, we are reiterating...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.